Currently, a fully humanized activating monoclonal anti-CD137 antibody has completed phase I and II trials for its anti-tumor properties in the context of melanoma, renal cell carcinoma, and ovarian cancer [19]. The gene discussed is TNFRSF9; the disease is neoplasm.